Home > Neurology > AAN 2022 > Multiple Sclerosis > AAN 2022 Highlights Podcast

AAN 2022 Highlights Podcast

Presented By
Robert van den Heuvel, Medicom

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
AAN 2022


In this episode (20.34 minutes), Medicom’s correspondent covers 6 presentations from the Annual Meeting of the American Academy of Neurology (AAN 2022), held in Seattle (WA, US) from 2-7 April 2022.
The topics discussed are:
  1. Ravulizumab in patients with generalised myasthenia gravis
    In the randomised, phase 3 CHAMPION MG trial, the terminal complement component 5 (C5) inhibitor ravulizumab provided rapid and sustained symptomatic improvements in patients with generalised myasthenia gravis (gMG) for up to 26 weeks. These effects were sustained after an additional 26 weeks of open-label treatment.

  2. IPX203 versus immediate release carbidopa-levodopa
    The RISE-PD study compared the safety and efficacy of IPX203 with immediate release carbidopa-levodopa (CD-LD) in Parkinson’s disease patients with motor fluctuations. IPX203, an investigational oral extended-release (ER) formulation of CD-LD, resulted in statistically significant improvement in “good on” time versus immediate release CD-LD, while requiring fewer daily dosages.

  3. Targeting senescent cells to treat age-related diseases
    How to target ageing? By clearing the brain of senescent cells, according to Dr Miranda Orr. Senolytics, including the combination of dasatinib plus quercetin, are therapeutic agents that can induce the death of senescent cells. The phase 2 trial StoMP-AD is now enrolling participants to investigate targeting senescent cells to treat Alzheimer’s Disease (AD).

  4. Possible first ever treatment of Rett syndrome
    A placebo-controlled, phase 3 study demonstrated that trofinetide is efficacious and has an acceptable safety profile in girls and women with Rett syndrome (RTT). Trofinetide could become the first-ever licensed treatment of RTT.

  5. Ublituximab versus teriflunomide in relapsing Multiple sclerosis patients
    In both the phase 3 ULTIMATE I and ULTIMATE II trial, ublituximab treatment demonstrated a statistically significant reduction in annualised relapse rate (ARR) and cumulative probability of first relapse compared with teriflunomide over a 96-week period.

  6. Brain implant helps paralysed patients to communicate
    In a first-in-human study, 4 completely paralysed patients with Amyotrophic lateral sclerosis (ALS) had a brain-computer interface (BCI) implanted. This so-called endovascular motor neuroprosthesis (MNP) was safe and allowed patients to control a computer by thought, so they could send emails, browse the web and, in one case, write a book.
Enjoy listening!


Posted on